secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0000728387-25-000010
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics appoints Maya Martinez-Davis, GSK US President, to board
--------------------------------------------------------------------------------

- Board expanded to 6; Martinez-Davis appointed as independent director effective Sept 3, 2025.
- She serves on Compensation and Nominations Committees; receives $60K annual cash retainer plus 75K options (max $450K fair value) vesting over 36 months.
- Martinez-Davis brings 20+ years pharma experience; currently leads GSK's US commercial business since 2019.
- Her prior roles include President of biopharma Latin America at Merck KGaA and senior roles at Pfizer and Mirati board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000072838725000010/0000728387-25-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000072838725000010/catx-20250902.htm
  HTML page:      https://secwatch.observer/filing/0000728387-25-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer